TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Show more
Location: 1 Great Valley Parkway, Malvern, PA, 19355, United States | Website: https://www.telabio.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
79.11M
52 Wk Range
$0.86 - $5.17
Previous Close
$2.07
Open
$2.11
Volume
79,538
Day Range
$2.00 - $2.17
Enterprise Value
77.03M
Cash
42.83M
Avg Qtr Burn
-9.234M
Insider Ownership
8.31%
Institutional Own.
78.19%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|